Daniel Mark James 4

What Happened

• Daniel Mark James, Chief Financial Officer of Atossa Therapeutics, was granted 63,000 restricted stock units (RSUs) on March 26, 2026. The award was reported on a Form 4 filed March 30, 2026. The RSUs were granted at $0.00 (no cash paid) and represent a contingent right to receive one share of common stock per RSU at vesting.

Key Details

• Transaction date: 2026-03-26; Report filed: 2026-03-30 (filed within the typical two-business-day window).
• Grant amount/price: 63,000 RSUs granted @ $0.00 (no purchase price).
• Vesting: RSUs vest in three equal annual installments on the first three anniversaries of March 26, 2026 (i.e., 21,000 RSUs vest each year, subject to the terms).
• Shares owned following the transaction: Not specified on the reported transaction (not disclosed in the provided Form 4 excerpt).
• Footnote: Each RSU is a contingent right to one share upon vesting; this is a grant/compensation award, not an open-market purchase or sale.

Context

• RSU grants are compensation/retention awards and do not involve immediate cash outlay; value to the insider depends on the company’s future stock price and fulfillment of vesting conditions.
• This grant should be viewed as an executive compensation event rather than a direct bullish or bearish market signal.